Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy

Filippi, Andrea Riccardo; Piva, Cristina; Giunta, Francesca; Bellò, Marilena; Chiappella, Annalisa; Caracciolo, Daniele; Zotta, Michela; Douroukas, Anastasios; Ragona, Riccardo; Vitolo, Umberto; Bisi, G; Ricardi, Umberto

doi:10.1016/j.ijrobp.2013.05.053

Cited by 37 publications

(19 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical practice, we frequently encounter patients in whom it is difficult to judge FDG-PET positivity. 39,40 Unfortunately, we could not evaluate the role of PET/CT in this study because of retrospective settings. Meanwhile, the very recent report from the IELSG-26 study clarified the role of PET/CT after treatment in PMBL patients.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan

et al. 2014

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan

et al. 2014

View full text Add to dashboard Cite

“…At 3 years, patients with scores of 1-3 had similar PFS (94% vs. 83%, p = .3) but higher OS (100% vs. 77%, p < .05) compared to patients with scores 4-5. Two-year OS of patients with a score of 5 was significantly worse than all other patients (33% vs. 100%, p < .0001) [54]. In a study from Japan (n = 112), 75% of post-treatment PET positive patients underwent RT.…”

Section: Role Of Radiation Therapymentioning

confidence: 85%

“…Consolidative mediastinal RT may improve response rate and long-term outcomes in PMBCL patients with residual disease after chemotherapy [10,34,35,37,54]. In an Italian study (n = 37), following rituximab-based chemotherapy (R-VACOP-B, R-CHOP14 and R-CHOP21), 67% had Deauville score of 3-5 on a PET-CT scan performed at a median of 28 days after the end of therapy.…”

Section: Role Of Radiation Therapymentioning

confidence: 99%

Primary mediastinal large B-cell lymphoma

Bhatt¹,

Mourya²,

Shrestha³

et al. 2015

Cancer Treatment Reviews

View full text Add to dashboard Cite

“…A study on 37 PMLBCL patients found that ~50% of PMBCL patients showed residual disease on PET scan following rituximab plus chemotherapy (24). A recent retrospective study on 63 PMLBCL patients treated with RCHOP showed that primary induction failure occurred in 13 (20.6%) patients (25).…”

Section: Discussionmentioning

confidence: 99%

Role of radiotherapy in the treatment of primary mediastinal large B-cell lymphoma

Wang

Liu

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The role of radiotherapy (RT) in the treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is unclear. In the present study, a retrospective analysis of 63 patients with PMLBCL treated with or without RT was performed to evaluate the role of RT. Clinical outcomes were calculated using the Kaplan-Meier method and were compared between patients who did and did not receive RT, using the log-rank test. A multivariate analysis was performed using Cox proportional hazards model. After chemotherapy, 35 patients received RT, and RT was found to be associated with significantly improved 5-year overall survival (OS) (87 vs. 58%; P=0.001) and 5-year progression-free survival (PFS) (75 vs. 39%; P=0.001) rates compared with patients without RT. The subgroup analysis on 35 patients who received rituximab plus chemotherapy showed that RT did not improve the 5-year OS (88 vs. 92%; P=0.814) or the 5-year PFS (78 vs. 65%; P=0.511) rates compared with patients without RT. On multivariate analysis, RT and the addition of rituximab were predictive of increased OS [RT: Hazard ratio (HR), 0.157; P=0.018; rituximab: HR, 0.156; P=0.009] and PFS (RT: HR 0.111, P=0.001; Rituximab: HR 0.231, P=0.002) rates. However, the role of RT in PMLBCL in the rituximab era is unclear. Further investigation of the role of RT in the era of targeted therapy is required.

show abstract

Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy

Cited by 37 publications

References 19 publications

Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan

Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan

Primary mediastinal large B-cell lymphoma

Role of radiotherapy in the treatment of primary mediastinal large B-cell lymphoma

Contact Info

Product

Resources

About